News

Pharmaceutical Technology on MSN1d
Coherus divests Udenyca franchise to Intas for up to $558.4m
Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.
Johnson & Johnson's Q1 Results, FY Guidance Highlight The 'Power Of The Pharma Portfolio'
Johnson & Johnson (JNJ) reported upbeat Q1 results amid an exciting earnings season, with analysts noting impressive sales ...
Gilead: HIV Franchise Woes Highlight Cancer Follies
Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...
Coherus Biosciences completes divestiture of UDENYCA franchise
Coherus BioSciences (CHRS) announced the completion of the previously announced divestiture of its UDENYCA franchise to Intas Pharmaceuticals ...
Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise
GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...
pharmaphorum4y
Servier beefs up in cancer, buying Agios’ oncology business for $1.8bn
French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on genetic ...
CNN1y
Royalty Pharma Plc Class A
Royalty Pharma Plc engages in the provision of drug ... Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta ...